Sight Sciences will report Q4 and full-year 2025 financial results on March 4, 2026, followed by a conference call.
Quiver AI Summary
Sight Sciences, Inc., an eyecare technology company, announced that it will release its financial results for the fourth quarter and full year ending December 31, 2025, after the market closes on March 4, 2026. Following the release, the company will hold a conference call at 1:30 p.m. Pacific Time to discuss the results, which can be accessed through a live and archived webcast on its website. Sight Sciences develops innovative technologies aimed at transforming eye care, including the OMNI and SION Surgical Systems for treating glaucoma and the TearCare System for addressing dry eye disease. The company strives to improve treatment paradigms with its minimally invasive solutions targeting common eye diseases.
Potential Positives
- Announcement of upcoming financial results provides transparency and allows for investor engagement through a scheduled conference call.
- Company's focus on innovative and minimally invasive eye care technologies positions it as a leader in addressing significant health challenges, particularly glaucoma and dry eye disease.
- The OMNI® and SION® Surgical Systems offer advanced solutions for glaucoma treatment, highlighting the company’s commitment to improving patient care.
Potential Negatives
- The announcement does not provide any preliminary insights into the company's financial performance for the fourth quarter and full year ended December 31, 2025, which may raise concerns among investors regarding ongoing financial stability or growth.
- The timing of the financial results announcement is close to the fiscal year-end, which could imply that the company may be facing challenges that it is not disclosing until the last moment.
- Investors are required to wait until March 4, 2026, for financial results, which prolongs uncertainty for shareholders and may lead to speculation or concern about the company's performance.
FAQ
When will Sight Sciences announce its financial results?
Sight Sciences will report its financial results on March 4, 2026, after market close.
What time is the Sight Sciences earnings conference call?
The conference call will begin at 1:30 p.m. Pacific Time on March 4, 2026.
How can I listen to the Sight Sciences conference call?
Investors can access the live and archived webcast at www.sightsciences.com under the News & Events section.
What are the key products of Sight Sciences?
Sight Sciences' key products include the OMNI® and SION® Surgical Systems, as well as the TearCare® System.
What conditions do Sight Sciences' technologies address?
The technologies are designed to treat glaucoma and evaporative dry eye disease, improving patient care and outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SGHT Insider Trading Activity
$SGHT insiders have traded $SGHT stock on the open market 26 times in the past 6 months. Of those trades, 1 have been purchases and 25 have been sales.
Here’s a breakdown of recent trading of $SGHT stock by insiders over the last 6 months:
- JEREMY B. HAYDEN (Chief Legal Officer) has made 0 purchases and 6 sales selling 75,209 shares for an estimated $547,941.
- PAUL BADAWI (President and CEO) has made 0 purchases and 4 sales selling 84,029 shares for an estimated $506,852.
- ALISON BAUERLEIN (Chief Operating Officer) has made 0 purchases and 3 sales selling 40,491 shares for an estimated $223,194.
- DAVID BADAWI (Chief Technology Officer) has made 0 purchases and 5 sales selling 20,529 shares for an estimated $124,890.
- STAFFAN ENCRANTZ purchased 13,958 shares for an estimated $115,963
- BRENTON TAYLOR (EVP, Operations & R&D) has made 0 purchases and 3 sales selling 15,628 shares for an estimated $108,412.
- JAMES RODBERG (Chief Financial Officer) has made 0 purchases and 4 sales selling 10,133 shares for an estimated $76,981.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SGHT Revenue
$SGHT had revenues of $19.9M in Q3 2025. This is a decrease of -1.25% from the same period in the prior year.
You can track SGHT financials on Quiver Quantitative's SGHT stock page.
$SGHT Hedge Fund Activity
We have seen 64 institutional investors add shares of $SGHT stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PATHSTONE HOLDINGS, LLC added 718,352 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,696,531
- PROSIGHT MANAGEMENT, LP removed 439,941 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,488,732
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC added 425,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,370,250
- WALLEYE CAPITAL LLC added 294,112 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,332,308
- BANK OF AMERICA CORP /DE/ added 202,210 shares (+194.8%) to their portfolio in Q4 2025, for an estimated $1,603,525
- INFORMED MOMENTUM CO LLC added 163,866 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,299,457
- APOLLO MANAGEMENT HOLDINGS, L.P. removed 160,466 shares (-23.9%) from their portfolio in Q4 2025, for an estimated $1,272,495
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SGHT Analyst Ratings
Wall Street analysts have issued reports on $SGHT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 12/10/2025
To track analyst ratings and price targets for $SGHT, check out Quiver Quantitative's $SGHT forecast page.
$SGHT Price Targets
Multiple analysts have issued price targets for $SGHT recently. We have seen 5 analysts offer price targets for $SGHT in the last 6 months, with a median target of $9.1.
Here are some recent targets:
- Adam Maeder from Piper Sandler set a target price of $9.0 on 01/05/2026
- Danielle Antalffy from UBS set a target price of $12.0 on 12/23/2025
- Joanne Wuensch from Citigroup set a target price of $9.1 on 12/11/2025
- Frank Takkinen from Lake Street set a target price of $12.0 on 12/10/2025
- Cecilia Furlong from Morgan Stanley set a target price of $8.0 on 12/02/2025
Full Release
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com , on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s
OMNI
®
Surgical System
and
OMNI
®
Edge Surgical System
are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The
SION
®
Surgical System
is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s
TearCare
®
System
is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit
www.sightsciences.com
for more information.
Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2026 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
[email protected]
Media contact:
[email protected]
